GLP-1 medications for teens: what 18 trials actually found

More teenagers are being prescribed GLP-1 medications than ever, and most parents are making that call with very little evidence in front of them. A new review in JAMA Pediatrics is the first to gather the trials into one place. It pooled 18 studies in more than 1,400 children and adolescents, and the picture is both more encouraging and more incomplete than the headlines suggest.

TL;DR

A JAMA Pediatrics review of 18 randomised trials in 1,402 children and teens found GLP-1 medications lowered weight, BMI and blood sugar, with no significant signal for suicidal thoughts or depression. The catch is time. The trials ran about six months on average, so what these drugs do to a still-growing body over years is genuinely unknown. Stomach side effects were common, and nutrition during the growth years is a gap parents have to manage themselves.

What the review actually looked at

The analysis was published in JAMA Pediatrics in December 2025. Rather than run a new trial, the team pooled 18 randomised controlled trials that had tested GLP-1 receptor agonists against a placebo in young people. Randomised and placebo-controlled matters here, because it means every result below is measured against what happened to similar kids who did not get the drug.

The combined group was 1,402 participants: 838 on a GLP-1 medication and 564 on placebo. The mean age was 13.7 years, the range ran from 6 to 17, and 59.3% were girls. Eleven of the trials were in obesity, six in type 2 diabetes, and one in prediabetes. The drugs studied included the ones parents will recognise, semaglutide (the medicine in Wegovy and Ozempic) and liraglutide (Saxenda), alongside older agents.

One number frames everything that follows. The median treatment length was 0.51 years, so around six months. This is short. Keep that in mind every time you read a reassuring result below, because six months in the life of a 13-year-old is not the same test as six months in a middle-aged adult.

What it found on weight and blood sugar

On the numbers that send families to the clinic in the first place, the medications worked. Compared with placebo, the pooled results were:

• Body weight: down 3.02 kg on average (95% confidence interval −4.98 to −1.06 kg).
• BMI: down 1.45 points (95% CI −2.40 to −0.49).
• HbA1c (average blood sugar over about three months): down 0.44% overall, and down 0.94% in the diabetes trials specifically (95% CI −1.25 to −0.62).
• Fasting glucose: down 9.92 mg/dL.
• Systolic blood pressure: down 2.73 mm Hg (95% CI −4.04 to −1.43).

A 3 kg average weight drop can look modest next to the double-digit percentages you read about with adult Wegovy. There is a reason for the gap. This average blends every drug and dose in the review, including older and weaker agents and short trial windows, so it pulls the strong performers and the weak ones into one middling figure. It is a floor, not a ceiling. The blood-sugar effect was the standout for the diabetes group, where a 0.94% cut in HbA1c is a clinically real improvement for a teenager with type 2 diabetes.

The safety question parents actually ask

For most families the real worry is not the scale, it is the mind. In 2023 regulators began looking at reports of suicidal thoughts in adults on GLP-1 drugs, and that headline stuck. So this is the finding parents will want first: the review found no significant increase in suicidal ideation or behaviour compared with placebo (log rate ratio −0.46, 95% CI −1.42 to 0.49), and no significant difference in depression either.

That is genuinely reassuring, but it needs one honest caveat. Only 5 of the 18 trials documented using a formal suicide-risk scale in their published results, despite FDA guidance recommending it. So part of the reason no signal showed up is that many trials were not measuring it carefully in the first place. Absence of evidence and evidence of absence are not the same thing. The practical takeaway does not change: watch for mood changes in any teenager on these drugs, and raise any history of depression or anxiety with the prescriber before starting.

The side effects that were real

Where the review did find a clear signal was the gut. Gastrointestinal adverse events were significantly more common on GLP-1 medications than on placebo, the same nausea, vomiting, diarrhoea and constipation that adults report. The authors singled these GLP-1 side effects out as the issue that warrants attention in any long-term plan, because a nauseated teenager who is skipping meals is a nutrition problem as much as a comfort one.

Most of this is managed the same way it is in adults: a slow climb up the dose, smaller and more frequent meals, and staying ahead of dehydration. The difference is that a growing body has less margin for a stretch of poor intake, which is where the next point comes in.

The limitation that matters most

Everything in this review rests on about six months of data. That is enough to show a drug lowers weight and blood sugar. It is nowhere near enough to answer the questions that actually keep parents up at night.

Adolescence is a window of rapid bone building, muscle development and, for many, active puberty and menstruation. We do not yet have trial data on what years of appetite suppression does to final adult height, peak bone mass, or long-term muscle development in this age group. Nor do these short trials tell us what happens when a teenager stops the drug, though the adult pattern of weight returning after stopping is well documented and there is no reason to assume young people are exempt. The honest summary is that the short-term case is now reasonably solid, and the long-term case is still an open question.

Nutrition during the growth years

This is the gap the trials do not close and families are left to manage. Suppressing appetite in a 50-year-old is one thing. Suppressing it in a 14-year-old who is still building the skeleton and muscle they will carry for life is a different proposition, and it is exactly where GLP-1 Shield focuses.

When a teenager eats far less, the protein and micronutrients that growth depends on get harder to hit. The nutrients most at risk are the same ones flagged across the adult evidence, and they matter even more during development: protein for muscle and growth, calcium and vitamin D for bone, iron (a particular concern given most participants here were girls, many of them menstruating), plus vitamin B12 and zinc. We covered how badly intake can fall in what GLP-1 users actually eat, and why muscle is the tissue to protect in what GLP-1 users need to know about muscle loss and protein intake.

One firm warning before anyone reaches for a supplement bottle. The doses discussed in our adult GLP-1 supplement protocol are for adults, not children, and some of them are deliberately high correction doses that would be unsafe for a teenager. Supplementing a young person on a GLP-1 drug should be guided by a pediatric clinician and, where relevant, by blood tests, not copied from an adult plan. The point is to protect growth, not to add a second risk on top of the first. For the wider picture of which nutrients tend to run low, our overview of nutrient deficiency on GLP-1 medications is a useful starting point for that conversation.

Frequently asked questions

Are Ozempic and Wegovy safe for teenagers?

In the JAMA Pediatrics review of 18 trials, GLP-1 medications lowered weight and blood sugar in adolescents with no significant rise in suicidal thoughts or depression. Gastrointestinal side effects like nausea and vomiting were significantly more common than with placebo. The honest limit is time: the trials ran about six months on average, so the long-term effect on a growing body is not yet known.

At what age can a child take a GLP-1 medication?

In the US, Wegovy (semaglutide) and Saxenda (liraglutide) are approved for chronic weight management in adolescents aged 12 and older, and some GLP-1 drugs are approved for type 2 diabetes in this age group. The trials in the JAMA Pediatrics review included children as young as 6, but that was in research settings. Any use in a child is a decision for a pediatric specialist, not an off-label experiment at home.

Do GLP-1 drugs cause depression or suicidal thoughts in teens?

This review found no significant increase in suicidal ideation or depression versus placebo in adolescents. That is reassuring, but only 5 of the 18 trials documented using a formal suicide-risk scale, so the evidence is thinner than the result sounds. Any teenager on these drugs should still be watched for mood changes, and a history of depression should be discussed with the prescriber first.

How much weight do teens lose on GLP-1 medications?

Across all 18 trials the pooled average was a 3.02 kg drop in body weight and a 1.45-point fall in BMI versus placebo. That average blends older, weaker drugs with newer ones like semaglutide, so results for any single drug vary widely. Blood sugar improvements were larger in the diabetes trials, with HbA1c falling 0.94% in that group.